Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
OBJECTIVES: Lung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors correlated with survival in patients with advanced NSCLC who had undergone hospice care only. METHODS: A total of 102 patients with recurrent stage III/IV NSCLC after traditional treatment failure were investigated. Survival was measured from the date of enrollment to December 2019 or the time of death. Tumor tissues were collected, and DNA sequencing was performed to identify somatic mutations. Data on clinical factors of patients were collected and analyzed by univariate and multivariate analyses. Overall survival analysis was conducted using the Kaplan-Meier method. RESULTS: The 6-month, 1-year, and 2-year overall survival rates of the 102 patients with metastatic NSCLC were 17.65%, 3.92%, and 0.98%, respectively. The median overall survival of the 102 patients was 3.15 months. Tumor location in the peripheral lung, epidermal growth factor receptor (EGFR) inhibitor history, low tumor mutation load, adenocarcinoma, and poor performance status score were associated with prolonged survival compared with tumor location in the central lung, no EGFR inhibitor history, high tumor mutation load, squamous cell carcinoma, and good performance status score (p=0.045, p=0.003, p=0.045, p=0.021, and p=0.0003, respectively). CONCLUSIONS: EGFR inhibitor treatment history and tumor mutation load are risk factors for the overall survival of patients with stage III/IV NSCLC who have undergone only hospice care. These results provide a critical clinical basis for further study of nontraditional anti-tumor responses induced by EGFR inhibitors.
Main Authors: | Lan,Yan, Zhou,Shuo, Feng,Weihong, Qiao,Ying, Du,Xueming, Li,Fenge |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Faculdade de Medicina / USP
2021
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100238 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
by: Bacchi,Carlos E., et al.
Published: (2012) -
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
by: Jorge,S.E.D.C., et al.
Published: (2014) -
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
by: Zükin,Mauro
Published: (2012) -
Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices
by: De Mello,Ramon Andrade, et al.
Published: (2012) -
Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor
by: Machado-Rugolo,J., et al.
Published: (2022)